Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Sells $32,200.00 in Stock

Tyme Technologies, Inc. (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the company’s stock in a transaction on Monday, June 7th. The shares were sold at an average price of $1.61, for a total transaction of $32,200.00. Following the sale, the insider now directly owns 24,538,546 shares in the company, valued at approximately $39,507,059.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Tuesday, June 1st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.58, for a total transaction of $31,600.00.
  • On Monday, May 24th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.35, for a total transaction of $27,000.00.
  • On Monday, May 17th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.31, for a total transaction of $26,200.00.
  • On Tuesday, May 11th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.23, for a total transaction of $24,600.00.
  • On Monday, April 26th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.54, for a total transaction of $30,800.00.
  • On Monday, April 19th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.45, for a total transaction of $29,000.00.
  • On Monday, April 12th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.57, for a total transaction of $31,400.00.
  • On Monday, April 5th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.78, for a total transaction of $35,600.00.
  • On Monday, March 29th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.73, for a total transaction of $34,600.00.
  • On Monday, March 22nd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $2.07, for a total transaction of $41,400.00.

Shares of TYME opened at $1.59 on Friday. Tyme Technologies, Inc. has a twelve month low of $0.85 and a twelve month high of $4.99. The stock has a market capitalization of $207.38 million, a P/E ratio of -7.57 and a beta of 1.04. The company has a fifty day moving average price of $1.48.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Axiom Investment Management LLC bought a new position in shares of Tyme Technologies in the first quarter worth about $161,000. Virtu Financial LLC grew its holdings in shares of Tyme Technologies by 933.6% in the first quarter. Virtu Financial LLC now owns 201,675 shares of the company’s stock worth $359,000 after purchasing an additional 182,163 shares during the last quarter. Millennium Management LLC bought a new position in shares of Tyme Technologies in the first quarter worth about $289,000. Morgan Stanley grew its holdings in shares of Tyme Technologies by 382.3% in the first quarter. Morgan Stanley now owns 276,924 shares of the company’s stock worth $493,000 after purchasing an additional 219,507 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. bought a new position in shares of Tyme Technologies in the first quarter worth about $178,000. Hedge funds and other institutional investors own 15.30% of the company’s stock.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.

Featured Article: Why is the price-sales ratio important?

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.